Drug
Incb054329 Monotherapy
Incb054329 Monotherapy: highest development phase Phase 1/2, developed by Incyte. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Incyte
Trials
| Drug | Phase | Indication |
|---|---|---|
| INCB054329 Monotherapy NCT02431260 | Phase 1/2 | Solid Tumors and Hematologic Malignancy |
Latest
No recent events.
Follow Incb054329 Monotherapy on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.